Short answer
Tvardi Therapeutics, Inc. (TVRD) filed an 8-K current report with the SEC on July 7, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.2). Filing furnishes Exhibits 99.1 and 99.2 under Regulation FD.
Tvardi Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Filing furnishes Exhibits 99.1 and 99.2 under Regulation FD
- Disclosure is not deemed filed under Exchange Act Section 18
- Exhibits are not incorporated by reference into other filings absent specific reference
Item EX-99.1 · Exhibit EX-99.2
- Phase 1 validated TTI-109’s prodrug conversion, dose-proportional exposure, and TTI-101-equivalent plasma levels
- STAT3-driven Th17, Tfh, and B-cell populations fell by up to 60%, providing exploratory target-engagement evidence
- Diarrhea duration improved substantially versus TTI-101: 0.46 days versus 3.35 days at near-equivalent doses
- Planned Phase 2 dermatologic and GI programs remain contingent on IND clearance and additional funding
- Positive data strengthen TTI-109’s development case, but healthy-volunteer results do not yet demonstrate clinical efficacy in patients
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tvardi Therapeutics, Inc. 8-K filings
Get the next TVRD 8-K as it lands
Follow TVRD for push alerts, or ask the research agent what this filing means.